Calculation of relative risks of fracture for romosozumab versus teriparatide.

Publication Details

Journal
Figshare
Published
2025-02-07
DOI
https://doi.org/10.1371/journal.pone.0299673.s003
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Calculation of relative risks of fracture for romosozumab versus teriparatide.

Figshare
HER2/EGFR in Cancer Research
article

Calculation of relative risks of fracture for romosozumab versus teriparatide.

article en

Abstract

No abstract available for this paper.
Figshare
Openalex Percentile: Top 41%
HER2/EGFR in Cancer Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Calculation of relative risks of fracture for romosozumab versus teriparatide. · Figshare (2025) | TGRS Research Map | TGRS